More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wave of Debt Payments Facing US Government
- HP Comes in As Expected; Is It Time to Buy?
- Paul: Audit the Fed
- JAL Slides to Record Low on Bankruptcy Jitters
- Hewlett-Packard Profit Rises, Matches Guidance
- Prepare For Large Decline In Stocks, Next Year?
- The Social Media Gaming Threat
- Why Amazon Rules Retail
- Holiday Travel Outlook
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
After a 2 a.m. start today, I thought I was done with work for the week and I was already cruising into the weekend. But, for this, I don't mind spending some time working from home on a Friday afternoon.
 |
Source: universityofcalifornia.com Dr. Susan Desmond-Hellmann |
], Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought. She's the company's President of Product Development and the one who many credit as being the driving force behind Genentech's successful drug development track record over the past several years. As one veteran biotech analyst once told me, "No one knows how to design oncology clinical trials better than Sue." I've always thought her third act (she was a practicing oncologist before going corporate) would be as the CEO of a big pharma. Her name was always on the rumored shortlist when spots opened up in recent years. But I was wrong. She's taking the untold millions of dollars she made at Genentech and appears to be going to the much lower-paying world of academia. You had to know something was up, perhaps, when Roche announced a management shakeup at Genentech and moved the good doctor into an "advisory role."
The University of California system this afternoon issued this press release announcing that Dr. Desmond-Hellmann has been nominated to be the next Chancellor of UC San Francisco. The UC Board of Regents will decide whether to approve her for the position at its meeting next week. If the board hires Dr. Desmond-Hellmann, she'd take over the campus, known for its clinical research, on August 3rd.
She's quoted in the press release as saying, "I began my career at UCSF, and my heart has never left it. I am delighted and humbled to have the Regents' consideration for the position of chancellor at this truly great institution. My life's work has been focused on making a difference for patients, and I cannot think of a better place than UCSF to carry that work forward." Well, I can, but USC isn't looking for a new president.
Anyway, the UC says the Regents will talk about salary behind closed doors and then vote on it in public. I'm almost certain she doesn't need the money and isn't doing it for that.
I hope she won't mind, but I wanted to share an email Dr. Desmond- Hellmann sent me last month in response to this blog that I did the day Genentech formally became apart of Roche.
"Your...blog...was incredibly touching to me," she wrote. "(It) was a reminder to me of why I am consistently inspired to try to do a better job, as too many patients need better therapies. So I am writing to convey a big thanks to you for the kind words and for capturing some of the spirit of why being in biotech (and hopefully covering it) is special beyond the business aspect."
I don't think you'll need it, but good luck next week, Sue. UCSF will be fortunate to have you.
Now, back to starting my weekend. No more work, alright?
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes